Integrated Drug Discovery
At Sai Life Sciences, Integrated Drug Discovery (IDD) offers a seamless, innovation-driven approach tailored to your program goals. We bring together medicinal chemistry, in vitro biology, structural biology, DMPK, pharmacology, and toxicology within a single, coordinated framework—enabling rapid iteration, informed decision-making, and scientific continuity.
Unified Science. Accelerated Progress.
Our integrated model combines depth of expertise with operational agility, allowing flexible engagement at any stage or across the full discovery continuum. From target validation to candidate nomination, we deliver cohesive strategies, transparent communication, and a shared commitment to scientific excellence—advancing programs efficiently and with confidence.
To date, we have supported:
- 300+ Discovery Programs across USA, EU & UK, and Asia
- Diverse therapeutic areas including Oncology, CNS, Metabolic Disorders, Inflammation, and others
- 40+ Programs advanced to different clinical phases (IND to Phase III)
- 18 months demonstrated turnaround time from Hit/Lead to Candidate Nomination
Our Capabilities in IDD
Target Identification & Validation
Apply advanced bioinformatics, assay development, and disease biology insights to identify and validate druggable targets with translational relevance.
Hit Identification
Leverage high-throughput screening, fragment-based discovery, and virtual screening to identify potent, selective hit molecules efficiently.
Hit-to-Lead Optimization
Integrate medicinal chemistry, structure-based design, and early ADME profiling to refine hits and prioritize the most promising leads.
Lead Optimization
Combine iterative design, SAR expansion, and predictive DMPK modeling to optimize potency, selectivity, and developability.
Candidate Selection
Deliver well-characterized preclinical candidates with robust efficacy, PK/PD, and safety profiles supported by integrated data packages.
Collaborative Flexibility
Engage at any stage or across the full discovery continuum through milestone-driven, transparent collaboration models tailored to program needs.
Our Capabilities in IDD
Target Identification & Validation
Apply advanced bioinformatics, assay development, and disease biology insights to identify and validate druggable targets with translational relevance.
Hit Identification
Leverage high-throughput screening, fragment-based discovery, and virtual screening to identify potent, selective hit molecules efficiently.
Hit-to-Lead Optimization
Integrate medicinal chemistry, structure-based design, and early ADME profiling to refine hits and prioritize the most promising leads.
Lead Optimization
Combine iterative design, SAR expansion, and predictive DMPK modeling to optimize potency, selectivity, and developability.
Candidate Selection
Deliver well-characterized preclinical candidates with robust efficacy, PK/PD, and safety profiles supported by integrated data packages.
Collaborative Flexibility
Engage at any stage or across the full discovery continuum through milestone-driven, transparent collaboration models tailored to program needs.
Facilities, Equipment, and Technical Capabilities
Sai Life Sciences offers state-of-the-art facilities and advanced technology platforms spanning chemistry, biology, DMPK, and toxicology. Our infrastructure includes automated synthesis, high-throughput screening, flow chemistry, and integrated data systems. Supported by cGMP- and GLP-compliant laboratories, we deliver precision, scalability, and reliability—enabling seamless progression from discovery to development with scientific and operational excellence.
Frequently Asked Questions
Our IDD platform unites Medicinal Chemistry, Computational Chemistry, Biology, DMPK, Toxicology, Analytical Sciences, and Process Chemistry to accelerate progression from target validation to candidate selection. This integrated, data-driven model ensures speed, quality, and a seamless transition from discovery to development.
We work across oncology, immunology, inflammation, pain, rare diseases, metabolic disorders, and central nervous system (CNS) indications, with capabilities in small molecules and targeted therapies. Our integrated workflows support discovery programs across diverse and complex therapeutic areas.
Integration is enabled through co-located core functions and a unified, fit-for-purpose program management system connecting medicinal chemistry, computational chemistry, biology, DMPK, toxicology, and in vivo pharmacology. Shared digital platforms, transparent communication, and global infrastructure in Boston, Hyderabad, and Manchester eliminate silos and accelerate decision-making from target validation to IND.
Timelines depend on project complexity; however, programs typically progress from hit identification to candidate nomination in 18–24 months. Co-located teams and unified program management enable faster decision-making while maintaining quality.
Yes. Flexible engagement models allow partners to begin with a defined phase or work package—such as hit identification, medicinal chemistry, or biology—before expanding to an end-to-end IDD solution. Custom labs and integrated teams ensure smooth onboarding, rapid execution, and full transparency for future scale-up.